key: cord-1052668-omwa9gvd
authors: de Assis, Rafael R.; Jain, Aarti; Nakajima, Rie; Jasinskas, Algis; Felgner, Jiin; Obiero, Joshua M.; Norris, Philip J.; Stone, Mars; Simmons, Graham; Bagri, Anil; Irsch, Johannes; Schreiber, Martin; Buser, Andreas; Holbro, Andreas; Battegay, Manuel; Hosimer, Philip; Noesen, Charles; Adenaiye, Oluwasanmi; Tai, Sheldon; Hong, Filbert; Milton, Donald K.; Davies, D. Huw; Contestable, Paul; Corash, Laurence M.; Busch, Michael P.; Felgner, Philip L.; Khan, Saahir
title: Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray
date: 2021-01-04
journal: Nat Commun
DOI: 10.1038/s41467-020-20095-2
sha: b3143560e1f337cf0f033e465c1826cf2896a26f
doc_id: 1052668
cord_uid: omwa9gvd

The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.

C OVID-19 caused by the SARS-CoV-2 virus is a worldwide pandemic with significant morbidity and mortality estimates from 0.5 to 2% of confirmed cases 1 . The current case definition for confirmed SARS-CoV-2 infection relies on PCR-positive pharyngeal or respiratory specimens, with testing largely determined by presence of fever or respiratory symptoms in an individual at high epidemiologic risk. However, this case definition likely underestimates true prevalence, as individuals who develop subclinical infection that does not produce fever or respiratory symptoms are unlikely to be tested, and testing by PCR of pharyngeal or respiratory specimens is only around 60-80% sensitive depending on sampling location and technique and the patient's viral load 2 . Widespread testing within the United States is also limited by the lack of available testing kits and testing capacity limitations of available public and private laboratories. Therefore, the true prevalence of SARS-CoV-2 infection is likely much higher than currently reported case numbers would indicate.

Serology can play an important role in defining the true prevalence of COVID-19, particularly for subclinical infection 2 . Early studies of serology demonstrate high sensitivity to detect confirmed SARS-CoV-2 infection, with antibodies to virus detected 1-2 weeks after symptom onset 3 . Unlike PCR positivity, SARS-CoV-2 antibodies are detectable throughout the disease course and persist beyond the symptomatic phase 4 . Multiple serologic tests have been developed for COVID-19 5 . However, these tests are limited to detection of antibodies against one or two antigens, and cross-reactivity with antibodies to other human coronaviruses that are present in all adults 6 is currently unknown, resulting in limitations in test performance 7 . Prior use of serology for detection of emerging coronaviruses focused on antibodies against the spike (S) protein, particularly the S1 domain, and the nucleocapsid protein (NP) 8 . However, the optimal combination of antigens to most accurately detect strain-specific coronavirus antibodies remains a subject of debate.

Protein microarray technology can be used to detect antibodies of multiple isotypes against hundreds of antigens in a high throughput manner 9,10 so is well suited to serologic surveillance studies. This technology, which has previously been applied to other emerging coronaviruses 11 , is based on detection of binding antibodies, which are well-correlated with neutralizing antibodies 12 but do not require viral culture in biosafety level 3 facilities. Recently, our group developed a coronavirus antigen microarray (CoVAM) that includes antigens from SARS-CoV-2 and tested it on human sera collected prior to the pandemic to demonstrate low cross-reactivity with antibodies from human coronaviruses that cause the common cold, particularly for the S1 domain 2 . Compared to other recently developed SARS-CoV-2 antigen microarrays 13,14 , the CoVAM described here includes more comprehensive coverage of seasonal human coronaviruses and more variants of the immunodominant spike protein. We describe the validation of this methodology using convalescent blood specimens from COVID-19 cases confirmed by positive SARS-CoV-2 PCR.

Construction of coronavirus antigen microarray. A coronavirus antigen microarray (COVAM) was constructed containing 61 antigens that are causes of acute respiratory infections, including 11 antigens from SARS-CoV-2. The viral antigens printed on this array are from epidemic coronaviruses including SARS-CoV-2, SARS-CoV, and MERS-CoV, common cold coronaviruses (HKU1, OC43, NL63, 229E), and multiple subtypes of influenza, adenovirus, metapneumovirus, parainfluenza, and respiratory syncytial virus as listed in Supplementary Table 2 . The SARS-CoV-2 antigens on this array include spike protein (S), including the receptor-binding (RBD), S1, and S2 domains and the whole protein (S1 + S2), nucleocapsid protein (NP), and papain-like protease (PLpro). There is a similar set of antigens represented on the array from SARS-CoV, MERS-CoV, and the four common cold coronaviruses.

Discrimination of SARS-CoV-2 convalescent blood specimens using coronavirus antigen microarray. To determine the antibody profile of SARS-CoV-2 infection, the differential IgG and IgM reactivity to these antigens was evaluated for 100 SARS-CoV-2 convalescent blood specimens from PCR-positive individuals (positive group) and 88 sera collected prior to the COVID-19 pandemic from naive individuals (negative control group). As shown in the heatmap (Fig. 1) , the positive group is highly reactive against SARS-CoV-2 antigens. The negative controls do not show high reactivity overall to SARS-CoV-2, SARS-CoV or MERS-CoV antigens despite showing high reactivity to the common cold coronavirus antigens. The discrimination of the positive and negative groups is much greater for IgG antibodies than for IgM antibodies, although the overall pattern of reactivity is similar. Both positive and negative groups included both serum and plasma, and no systematic differences were observed between antibody response detected in serum versus plasma specimens. The two groups do not differ significantly in reactivity to antigens from common cold coronaviruses or other respiratory viruses for either IgG or IgM.

With respect to specific antigens, the positive group displays high IgG reactivity to SARS-CoV-2 NP and S antigens, including RBD, S1, and S2 domains (Fig. 2) . The positive group also demonstrates IgM and IgG cross-reactivity against NP and S2containing antigens from other betacoronaviruses (e.g., SARS, MERS, HKU1, OC43), while the negative group demonstrates low-level cross-reactivity to these antigens from SARS-CoV-2, likely due to high sequence homology of NP and S2 antigens among betacoronaviruses.

As an additional control, an earlier iteration of the CoVAM was tested against a separate set of pre-pandemic sera of 144 individuals that were monitored for acute respiratory virus infections including with seasonal betacoronaviruses. These individuals showed similar antibody cross-reactivity against SARS-CoV-2 antigens as the negative group ( Supplementary  Fig. 1 ). The two iterations of the CoVAM were printed and probed separately but demonstrated similar results indicating assay reproducibility.

Determination of optimal antigen combinations to detect SARS-CoV-2 infection. The differences between the groups appear to be restricted to SARS-CoV-2 antigens, so these antigens were the focus of subsequent analysis. The performance of all SARS-CoV-2 antigens on the CoVAM was defined based on differential reactivity in positive and negative controls using Receiver Operating Characteristic (ROC) Area Under Curve (AUC) with optimal cutoff chosen to achieve high specificity (Tables 1 and 2 ). For a selection of high-performing antigens for IgG and IgM, the ROC curves and differential reactivities between positive and negative controls are shown in Supplementary Figs. 2, 3. Among individual antigens for detection of IgG and IgM, S1 and RBD antigens demonstrated higher performance overall than NP and S2 antigens, while PLpro demonstrated the lowest performance.

In order to estimate the gain in performance by combining antigens, all possible combinations of antigens were tested in silico for performance in discriminating the positive and negative groups. The ROC curve with AUC, sensitivity, and specificity was calculated for each combination. The top-performing antigen combinations of each length are shown in Tables 3, 4 , while complete data for all combinations is reported in Supplementary Data 1 in Supplementary information. For both IgG and IgM, there is a clear gain in performance by combining up to 4 antigens as shown in Fig. 3 . However, for combinations of more than 4 antigens, test performance decreases due to decreasing specificity. The optimal antigen combinations include S1 and RBD antigens for both IgG and IgM but also include NP antigen for IgG and S2 antigen for IgM. These optimal combinations are not entirely predictable from the performance of individual antigens indicating that individual antigens are not orthogonal.

The performance of the assay can be further improved by combining IgG and IgM. For detection of prior SARS-CoV-2 infection at least 7 days post symptom onset, the combination of IgG and IgM achieves overall sensitivity 87.8% and specificity 98.9% for a high-specificity threshold and sensitivity 92.9% and specificity 97.7% for a high-sensitivity threshold. 

This study reveals several insights into the antibody response to SARS-CoV-2 infection with implications for vaccine development. The antibody profiles of naive individuals include high IgG reactivity to common cold coronaviruses with low-level crossreactivity with NP and S2 domains from SARS-CoV-2 and other epidemic coronaviruses, which is not surprising given the high degree of sequence homology and previously observed serologic cross-reactivity 15 between NP and S2 domains of betacoronaviruses, a group that includes SARS-CoV-2, SARS-CoV, MERS, and common cold coronaviruses HKU1 and OC43. This low-level cross-reactivity occurs in approximately 7% of unexposed individuals (Fig. 1) , which leads to hypotheses regarding whether these individuals differ in COVID-19 susceptibility and outcomes. The low-level antibody cross-reactivity of a subset of unexposed individuals for SARS-CoV-2 spike protein containing NP; S1; S1.mFcTag 0.6056 0.9858 0.9857 4 NP; S1; S1.mFcTag; Spike.RBD.Bac 0.6004 0.9861 0.986 5 NP; S1; S1.mFcTag; S1+S2; S2 0.7895 0.9835 0.9835 6 NP; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.Bac; Spike.RBD.His.HEK 0.8077 0.9816 0.9816 7 NP; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.Bac; Spike.RBD.His.HEK 0.8566 0.9779 0.9779 8 NP; Pl.pro; S1; S1.HisTag; S1.mFcTag; S1+S2; Spike.RBD.Bac; Spike.RBD.rFc 0.9147 0.9749 0.9749 9 NP; Pl.pro; S1; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike.RBD.rFc 0.9169 0.9645 0.9645 10 NP; Pl.pro; S1; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike.RBD.rFc 0.9128 0.9567 0.9567 11 NP; Pl.pro; S1; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike. RBD.rFc 0.918 0.9358 0.9359

Test performance characteristics for discrimination of positive and negative sera were derived for each high-performing antigen combination using ROC analysis with high specificity threshold, with optimal antigen combination in bold. This study also informs antigen selection and design for population surveillance and clinical diagnostic assays. The optimal binding antibody assay to discriminate SARS-CoV-2 convalescent sera from pre-pandemic sera is a combination of 4 antigens that include S1, RBD, and either S2 or NP. As individual antigens, NP and S2 demonstrate cross-reactivity with negative control sera which leads to lower specificity, but these antigens add predictive power when combined with the more specific S1 and RBD antigens. Larger combinations of antigens actually show decreased predictive power due to decreased specificity. In addition, differences among variants with different purification tags indicate that these tags may have a significant effect on the antigen conformation resulting in differences in antibody binding.

The overall diagnostic performance of this CoVAM is within range of existing serodiagnostic tests for SARS-CoV-2 7 . However, most existing serodiagnostic tests for SARS-CoV-2 do not report validation data as early as 7 days post symptom onset, and when examining only specimens collected at least 14 days post symptom onset, CoVAM performs better than individual antigen assays. Future variants of the CoVAM can include additional antigens that have shown some potential in selectively diagnosing coronavirus infections 16 .

The coronavirus antigen microarray can be useful both as an epidemiologic tool and as a research tool. The high throughput detection of SARS-CoV-2-specific antibody profiles that reliably distinguish COVID-19 cases from negative controls can be applied to large-scale population surveillance studies for a more accurate estimation of the true prevalence of disease than can be achieved with symptom-based PCR testing. Recent development of more portable digital microscope technology that can be Pl.pro; S1; S1.mFcTag; S1.RBD; Spike.RBD.His.HEK 0.7021 0.987 0.9868 6

Pl.pro; S1; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.His.HEK 0.748 0.9855 0.9854 7 NP; S1; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.His.HEK; Spike.RBD.rFc 0.7519 0.9842 0.9841 8

Pl.pro; S1; S1.mFcTag; S1.RBD; S1+S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike.RBD.rFc 0.7647 0.981 0.9809 9 S1; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike.RBD.rFc 0.7904 0.9757 0.9757 10 NP; S1; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike.RBD.rFc 0.7963 0.9675 0.9675 11 NP; Pl.pro; S1; S1.HisTag; S1.mFcTag; S1.RBD; S1+S2; S2; Spike.RBD.Bac; Spike.RBD.His.HEK; Spike. RBD.rFc 0.7958 0.961 0.961

Test performance characteristics for discrimination of positive and negative sera were derived for each high-performing antigen combination using ROC analysis with high specificity threshold, with optimal antigen combination in bold.

SARS.CoV.2.S1.HisTag SARS.CoV.2.S1.RBD SARS.CoV.2.S1+S2 SARS.CoV.2.S1

Combined SARS.CoV.2.S1.HisTag SARS.CoV.2.S1.RBD SARS.CoV.2.S1+S2 SARS.CoV.2.S1 integrated with smartphones will facilitate field implementation of the CoVAM. In addition, detection of these antibodies in SARS-CoV-2 convalescent plasma donations can provide validation prior to clinical use for passive immunization. The variation in the SARS-CoV-2 antibody profiles among acute and convalescent donors suggests that epitope characterization of convalescent donor plasma will be informative for evaluation of passive immune therapy efficacy in COVID-19 patients. The central role of inflammation in the pathogenesis of severe COVID-19 17 can be more closely studied by analyzing both strain-specific and cross-reactive antibody responses, particularly to test hypotheses regarding antibody-dependent enhancement with critical implications for vaccine development 18 .

In conclusion, a coronavirus antigen microarray containing a panel of antigens from SARS-CoV-2 in addition to other human coronaviruses was able to reliably distinguish convalescent plasma of PCR-positive COVID-19 cases from negative control sera collected prior to the pandemic. Antigen combinations demonstrated improved performance compared to each individual antigen. Further studies are needed to apply this methodology to large-scale serologic surveillance studies and to correlate specific antibody responses with clinical outcomes.

Specimen collection. A total of 135 de-identified SARS-CoV-2 convalescent blood specimens were collected from nasopharyngeal PCR-positive individuals from different sources with associated data on timing of symptom onset, positive PCR test, and collection (Supplementary Table 1 ). Of these convalescent specimens, 100 were collected from unique individuals at least 7 days post symptom onset so were used as positive controls, while 99 were collected longitudinally and used for the purpose of studying test performance as a function of time since symptom onset, with some overlap between the groups. A total of 88 de-identified pre-pandemic blood specimens were collected prior to November 1, 2019 from healthy blood donors and were used as negative controls. In addition, 144 specimens were collected between November 2018 and May 2019 from college students for a larger study of the contagious phenotype 19 and include specimens from individuals with acute respiratory virus infection, including seasonal coronaviruses. All biological specimens used in this study were collected under the auspices of local regulatory authorities governing protection of human research subjects with informed consent including future research use authorization.

Specimen testing on coronavirus antigen microarray. The coronavirus antigen microarray used in this investigation includes 60 antigens across respiratory virus subtypes, including 11 antigens from SARS-CoV-2 expressed in either baculovirus or HEK-293 cells (Supplementary Table 2 ). These antigens were provided by Sino Biological U.S. Inc. (Wayne, PA) as either catalog products or custom synthesis service products. The antigens were printed onto microarrays, probed with human sera, and analyzed as previously described 10, 20, 21 .

Briefly, lyophilized antigens were reconstituted with sterile water to a concentration of 0.1 mg/mL bringing protein solution to 1× phosphate-buffered saline (PBS) and printing buffer was added. Antigens were then printed onto ONCYTE AVID nitrocellulose-coated slides (Grace Bio-Labs, Bend, OR) using an OmniGrid 100 microarray printer (GeneMachines). The microarray slides were probed with human sera diluted 1:100 in 1x Protein Array Blocking Buffer (GVS Life Sciences, Sanford, ME) overnight at 4°C and washed with T-TBS buffer (20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20 in ddH 2 O adjusted to pH 7.5 and filtered) 3 times for 5 min each. A mixture of human IgG (Grace Bio-Labs SKU 110610) and IgM (Grace Bio-Labs SKU 110630), or IgG and IgA (Grace Bio-Labs SKU 110620), secondary antibodies conjugated to quantum dot fluorophores Q800 and Q585, respectively (antibodies obtained from Grace Bio-Labs, Bend, O) was applied to each of the microarray pads and incubated for 2 h at room temperature, and pads were then washed with T-TBS 3 times for 5 min each and dried. The slides were imaged using ArrayCam imager (Grace Bio-Labs, Bend, OR). Spot quantification (median spot fluorescence) and background signal subtraction was performed using the software ScanArray Express (PerkinElmer) version 3.0. Nonspecific binding of secondary antibodies was subtracted using saline control. Mean fluorescence of the 4 replicate spots for each antigen was used for analysis.

Statistics and reproducibility. The mean fluorescence intensity (MFI) of each antigen was determined by the average of the median fluorescence signal of four replicate spots. The fluorescence signal for each spot was determined by its signal intensity subtracted by the background fluorescence. All statistical analyses were conducted using R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria). All analysis and figures are representative of a single probing experiment.

MFI was normalized by the quantile normalization method using the normalize. quantiles.use.target function from the preprocessCore package (version 1.50.0). As a reference for normalization, a vector containing the median MFI for IgG or IgM was constructed. Descriptive statistics were used to summarize the IgM and IgG reactivity measured as MFI. Wilcoxon tests with p < 0.05 were used to compare the mean differences between groups.

In order to rank the individual antigens and combinations of antigens from SARS-CoV-2 for performance in discriminating the positive and negative groups, the receiver operating characteristic area under the curve (ROC AUC) values as well as sensitivity and specificity (derived from a logistic regression model) values for each antigen or combination of antigens were calculated by comparing positive and negative specimens using the pROC package (version 1.16.2) and the stats package (version 4.0.0). For this, the samples were randomly partitioned into two groups, at a ratio of 70%/30%, using the caret package (version 6.0-86). The group with 70% (training set) of the samples was used to create a logistic regression model using the glm function form the stats package (version 4.0.0). The 30% (testing set) subset was used to predict the outcome of each sample being classified as negative or positive using the stat package and the performance (sensitivity and specificity) calculated. This process was repeated 500 times and the final sensitivity, specificity, and AUC values were calculated as the mean values of all repetitions. All individual antigens and combinations of antigen were ranked based on the ROC AUC analysis above, and the top-performing combinations were further tested using the full sample set. The coordinates of the ROC curve were obtained (coords function from the pROC package) and the candidate combinations were compared to select the highest sensitivity at specificity equal to 1. Data visualization was performed using the ggplot2 package (version 3.3.0) or pROC package.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

The raw data that support the findings of this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

The complete custom R scripts used for data analysis are publicly available at the GitHub repository: https://doi.org/10.5281/zenodo.4146101.

Received: 3 May 2020; Accepted: 10 November 2020;

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and metaanalysis

The laboratory diagnosis of COVID-19 infection: current issues and challenges

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Evaluation of nucleocapsid and spike protein-based ELISAs for detecting antibodies against SARS-CoV-2

First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood

Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

Use of an influenza antigen microarray to measure the breadth of serum antibodies across virus subtypes

Specific serology for emerging human coronaviruses by protein microarray

Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution

An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus. Can

Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus

COVID-19 infection: the perspectives on immune responses

Avoiding pitfalls in the pursuit of a COVID-19 vaccine

Ventilation and laboratory confirmed acute respiratory infection (ARI) rates in college residence halls in College Park

Evaluation of quantum dot immunofluorescence and a digital CMOS imaging system as an alternative to conventional organic fluorescence dyes and laser scanning for quantifying protein microarrays

Protein microarray analysis of the specificity and crossreactivity of influenza virus hemagglutinin-specific antibodies

The coronavirus antigen microarray was designed by S. Khan and P. Felgner and was constructed by R. Nakajima and A. Jasinskas at UCI. The positive COVID-19 convalescent blood specimens and negative control specimens were collected as research specimens by L. Corash, A. Bagri, and J. Irsch at Cerus; M. Busch, G. Simmons, M. Stone, and P. Norris at Vitalant; M. Schreiber at OHSU; P. Hosimer, C. Noesen, and P. Contestable at Ortho Clinical Diagnostics; and A. Buser, A. Holbro, and M. Battegay at University Hospital Basel. A set of negative control sera used to validate an earlier iteration of the CoVAM were collected as research specimens for the Prometheus-UMD consortium by D. Milton, O. Adenaiye, S. Tai, and F. Hong at UMD. The testing of specimens on the coronavirus antigen microarray was performed by A. Jain and J. Felgner at UCI. The data analysis was performed by R. de Assis and J. Obiero at UCI. The manuscript and figures were prepared by S. Khan and R. de Assis with input and approval from all other authors.

The coronavirus antigen microarray is the intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA), a private company for which P. Felgner is the largest shareholder and several co-authors (R. de Assis, A. Jain, R. Nakajima, A. Jasinskas, J. Obiero, Jiin Felgner, H. Davies, and S. Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. The convalescent plasma used in this study was collected for clinical use by independent blood centers using licensed plasma or platelet processing systems manufactured by Cerus Corporation, for which multiple authors (L. Corash, A. Bagri, and Johannes Irsch) are shareholders and employees. Convalescent sera were also provided by Ortho Clinical Diagnostics, which is using these specimens to validate a clinical diagnostic test, and P. Hosimer, C. Noesen, and P. 

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-20095-2.Correspondence and requests for materials should be addressed to S.K.Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.Reprints and permission information is available at http://www.nature.com/reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.